skip to Main Content
Highmark BCBS

Highmark Blue Cross Blue Shield July 2017 Medical Policy Updates

Highmark Blue Cross Blue Shield July 2017 Medical Policy Updates »

July 2017 updated medical policies:

Revised Criteria for Trastuzumab (Herceptin)
Infliximab Criteria Revised to Include Infliximab-abda (Renflexis)
Revised Criteria for Agalsidase Beta (Fabrazyme)
Revised Criteria for Gemcitabine HCL, (Gemzar)
Coverage Criteria Changes for Paclitaxel, albumin-bound, Abraxane
Coverage Criteria Changes for Paclitaxel (Taxol)
Coverage Criteria Changes for Docetaxel (Taxotere)
Coverage Criteria Revised for Plerixafor (Mozobil)
Revised Criteria for Abatacept (Orencia)
Coverage Criteria for Ranibizumab (Lucentis) Revised
Coverage Criteria Changes for Panitumumab (Vectibix)
Coverage Criteria Revised for Fulvestrant (Faslodex)
Revised Criteria for Brentuximab Vedontin (Adcetris)
Coding Update for Galsulfase (Naglazyme)
Revised Criteria for Home Apnea Monitors
Criteria Revised for Laboratory Testing for Novel Influenza A (H1N1)
Revised Criteria for Cardiac Ablation Procedures
Criteria Updated for Acute Graft Versus Host Disease
Place of Service Revised and Facility Criteria Applied to Hematopoietic Stem-Cell Transplantation for HodgkinLymphoma
Coverage Criteria Revised and Facility Criteria Added for Magnetic Resonance Imaging (MRI) of the Breast
Coverage Criteria Revised for Docetaxel (Taxotere)
Infliximab (Remicade) Criteria Revised to Include Infliximab-abda (Renflexis)
Coverage Criteria Revised for Gemcitabine HCL, (Gemzar)
Coverage Criteria Changes for Paclitaxel (Taxol)
Coverage Criteria Revised for Paclitaxel, (Abraxane)
Coverage Criteria Revised for Plerixafor (Mozobil)
Coverage Criteria Revised for Trastuzumab (Herceptin)
Coverage Criteria for Ranibizumab (Lucentis) Revised
Coverage Criteria Changes for Panitumumab, (Vectibix)
Coverage Criteria Revised for Fulvestrant (Faslodex)
Coverage Criteria Revised for Decitabine (Dacogen)
Coverage Criteria Revised for Agalsidase Beta, (Fabrazyme)
Coverage Criteria Revised for Brentuximab Vedontin (Adcetris)

Highmark Blue Cross Blue Shield July 2017 Medical Policy Updates »

 

 

Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!

Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.

Back To Top